v3.26.1
Taxation (Tables)
3 Months Ended
Mar. 31, 2026
Taxation [Abstract]  
Schedule of Income Tax Benefit

The income tax benefit consisted of the following components:

 

   For the three months ended
March 31,
 
   2025   2026 
   (Unaudited)   (Unaudited) 
Current income tax expense  $58   $119 
Deferred income tax (benefit)/expense   (142)   329 
Total income tax (benefit)/expense  $(84)  $448 
Schedule of Benefit for Income Taxes and the Provision at the PRC, Mainland Statutory Rate

A reconciliation between the Group’s actual benefit for income taxes and the provision at the PRC, mainland statutory rate, is as follows:

 

   For the three months ended
March 31,
 
   2025   2026 
   (Unaudited)   (Unaudited) 
(Loss)/Income before income tax expense  $(3,731)  $2,008 
Computed income tax benefit with statutory tax rate   (932)   502 
Additional deduction for research and development expenses   (95)   (158)
Tax effect of preferred tax rate   254    (646)
Tax effect of favorable tax rates on small-scale and low-profit entities   140    (36)
Tax effect of non-deductible items   26    21 
Changes in valuation allowance   523    765 
Income tax (benefit)/expense  $(84)  $448 
Schedule of Deferred Tax Assets

As of December 31, 2025 and March 31, 2026, the significant components of the deferred tax assets are summarized below:

 

   As of
December 31,
   As of
March 31,
 
   2025   2026 
     (Audited)   (Unaudited) 
Deferred tax assets:        
Temporary difference in accounts receivable recognition  $5,815   $5,894 
Temporary difference in research and development costs   2,995    3,033 
Accrued expense   408    414 
Net operating loss carried forward   11,961    12,896 
Share-based compensation   538    546 
Allowance for credit losses   4,033    3,754 
Total deferred tax assets   25,750    26,537 
Valuation allowance   (13,803)   (14,756)
Deferred tax assets, net of valuation allowance  $11,947   $11,781 
Schedule of Changes in Valuation Allowance

Changes in valuation allowance are as follows:

 

   As of
December 31,
   As of
March 31,
 
   2025   2026 
     (Audited)   (Unaudited) 
Balance at the beginning of the period  $13,840   $13,803 
(Reversals)/Additions   (642)   763 
Foreign currency translation adjustments   605    190 
Balance at the end of the period  $13,803   $14,756 
Schedule of Net Operating Loss Carryforwards

As of March 31, 2026, net operating loss carryforwards will expire, if unused, in the following amounts:

 

2026  $4,679 
2027   17,419 
2028   14,836 
2029   6,920 
2030   7,062 
2031   3,597 
Indefinite   82,378 
Total  $136,891